News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thermo Fisher Scientific (TMO)'s $3.2 Billion Bond Sale Criticized


12/6/2013 8:25:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Analysts at one investment firm are already criticizing Thermo Fisher’s $3.2 billion bond offering announced yesterday, saying the move will likely increase the company’s debt load to risky levels. The scathing report was issued this morning by Gimme Credit, a fixed-income research firm, and followed news that Fitch Ratings had lowered the Waltham medical device giant’s credit rating by a notch to BBB and that Moody’s Investors Service said it probably will do the same once the bond sale closes. The Gimme Credit report questioned Thermo Fisher’s “ever-increasing appetite for debt” as the company works to raise the capital needed to complete its $13.6 billion acquisition of Carlsbad, Calif.-based Life Technologies.

Help employers find you! Check out all the jobs and post your resume.

Read at Boston Business Journal
Read at Bloomberg
Read at Genome Web

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES